Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Suyash Kulkarni is active.

Publication


Featured researches published by Suyash Kulkarni.


Journal of Vascular and Interventional Radiology | 2011

Research Reporting Standards for Radioembolization of Hepatic Malignancies

Riad Salem; Robert J. Lewandowski; Vanessa L. Gates; Ravi Murthy; Steven C. Rose; Michael C. Soulen; Jean Francois H Geschwind; Laura Kulik; Yun Hwan Kim; Carlo Spreafico; Marco Maccauro; Lourens Bester; Daniel B. Brown; Robert K. Ryu; Daniel Y. Sze; William S. Rilling; Kent T. Sato; Bruno Sangro; José Ignacio Bilbao; Tobias F. Jakobs; Samer Ezziddin; Suyash Kulkarni; Aniruddha V. Kulkarni; David M. Liu; David Valenti; Philip Hilgard; Gerald Antoch; Stefan Müller; Hamad Alsuhaibani; Mary F. Mulcahy

Primary Liver Tumors Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver; its incidence is increasing worldwide. It ranks as the sixth most common tumor and third most common cause of cancer-related mortality (1,2). Primary liver tumors include HCC and intrahepatic cholangiocarcinoma. Surgical resection is preferred over transplantation and is considered potentially curative in patients with resectable HCC and normal liver function (3). Transplantation is considered the gold standard for patients with unresectable HCC and whose disease is within the Milan criteria (4). Resection and transplantation have limited roles, given advanced disease (chronic liver disease and/or tumor extent) at presentation and limited organ availability (5–7). Chemoembolization and radiofrequency ablation represent standard therapies in treating patients and serve as a bridge to transplantation in selected patients (8,9). Radioembolization has an emerging role in “bridging” patients within criteria by delaying tumor progression. It has also been shown to downstage disease beyond the Milan, to within, transplant criteria (10–12). A recent study has demonstrated that radioembolization leads to longer time-to-progression and better toxicity profile when compared with chemoembolization (13). Patients with macrovascular tumor involvement have also exhibited evidence of clinical benefit after radioembolization (14).


Radiographics | 2011

Therapeutic Response to Radiofrequency Ablation of Neoplastic Lesions: FDG PET/CT Findings

Nilendu Purandare; Venkatesh Rangarajan; Sneha Shah; Anshu R. Sharma; Suyash Kulkarni; Aniruddha V. Kulkarni; Sumeet G Dua

Ablation of neoplastic lesions by using radiofrequency energy is gaining popularity in clinical practice because of the minimally invasive nature of radiofrequency ablation (RFA). Primary and secondary tumors of the liver and lung are treated with RFA when surgery is precluded because of comorbidity. Benign bone tumors are also treated with RFA to relieve pain and prevent further tumor growth. Differentiation between postablation tissue changes and residual disease is difficult with morphologic imaging modalities such as ultrasonography, computed tomography (CT), and magnetic resonance (MR) imaging, thus limiting the use of these modalities to detection of residual disease early after RFA. Fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) is a functional imaging modality that can be used to study the effects and efficacy of RFA. Lesions that show increased FDG uptake at PET become completely photopenic immediately after RFA, a finding that is suggestive of the completeness of ablation. Focal areas of increased FDG uptake within the ablated zone are suggestive of residual disease. Reactive tissue changes such as inflammation are depicted in the periphery of the ablated lesion and show a uniform low-grade FDG uptake, which can be differentiated from the focal, nodular intense uptake in areas of residual disease. Use of combined FDG PET/CT to detect residual disease early after RFA allows ablation to be repeated, if necessary, to obtain the maximum therapeutic benefit. Note that FDG uptake in the complications sometimes associated with RFA can be a cause of potential false-positive PET results.


Nuclear Medicine Communications | 2013

18F-FDG PET/CT-directed biopsy: does it offer incremental benefit?

Nilendu Purandare; Aniruddha V. Kulkarni; Suyash Kulkarni; Diptiman Roy; Archi Agrawal; Sneha Shah; Venkatesh Rangarajan

PurposeTo study whether the metabolic information provided by a prior PET/computed tomography (CT) scan can add valuable information and an incremental benefit while performing image-guided biopsies. MethodsFluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT findings of 112 patients were available before biopsy and were considered for analysis. Biopsies were performed using standard techniques only after the needle tip was confirmed to be in the portion of the lesion corresponding to the hypermetabolic area seen on PET. This was achieved by visual coregistration and also by software registration algorithms that registered the intraprocedural CT images with the preselected PET/CT data. Only those biopsies for which a definitive histopathological diagnosis could be made were considered ‘diagnostic’. Cases in which PET/CT added an incremental value were divided into three categories. ResultsA total of 112 patients (66 male and 46 female, age range 16–74 years) underwent a biopsy based on PET findings. The biopsy sites were as follows: lung, 54; lymph nodes, 27; bone, 12; and soft-tissue masses/deposits, 19. Out of the 112 biopsies, an incremental benefit was seen overall in 53 patients (47.3%): in 40.7% (22/54) of patients who underwent lung biopsies, 44.4% (12/27) of those who underwent lymph node biopsies, 66.6% (8/12) of those who underwent bone biopsies and 57.8% (11/19) of those who underwent soft-tissue biopsies. Out of the cases that showed an incremental benefit, the highest number (30) belonged to the category in which the biopsy sample was obtained from the focal hypermetabolic portion of the apparently larger morphological lesion seen on CT. ConclusionPET/CT data coregistered with intraprocedural CT images can guide needle placement in the viable portion of the lesion, thus increasing the chances of achieving a definitive diagnosis. This approach can offer a significant incremental benefit while performing image-guided biopsies.


Annals of Thoracic Medicine | 2008

Percutaneous computed tomography-guided core biopsy for the diagnosis of mediastinal masses

Suyash Kulkarni; Aniruddha V. Kulkarni; Diptiman Roy; Meenakshi Thakur

AIM: To describe various approaches of computed tomography (CT)-guided core biopsy and evaluate its ability to obtain adequate tissue for the assessment of mediastinal masses. MATERIALS AND METHODS: Between February 2004 and October 2006, 83 percutaneous CT-guided biopsies of mediastinal lesions were performed on 82 patients under local anesthesia. Coaxial needles were used and minimum of 3-4 cores were obtained. Post-biopsy CT scan was performed and patients observed for any complications. Tissue samples were taken to Pathology Department in formalin solution. RESULTS: From the 83 biopsies, adequate tissue for histological diagnosis was obtained in 80 (96%), and the biopsy was considered diagnostic. Of the 80 diagnostic biopsies, 74 biopsy samples were definitive for neoplastic pathology and 6 biopsy samples revealed no evidence of malignancy. There were no major complications. Minor complications were recorded in 5 patients. CONCLUSION: Percutaneous image-guided core biopsy of mediastinal lesions is an accurate, safe and cost-effective tool for the initial assessment of patients with mediastinal masses.


Future Oncology | 2015

Neoadjuvant chemotherapy in patients with locally advanced gallbladder cancer

Bhawna Sirohi; Abhishek Mitra; Jagannath P; Ashish Singh; Mukta Ramadvar; Suyash Kulkarni; Mahesh Goel; Shailesh V. Shrikhande

AIM Surgery is the only curative option for patients with gallbladder cancer (GBC). This study looks at the outcome of patients treated with neoadjuvant chemotherapy (NACT). PATIENTS & METHODS This is retrospective analysis of the prospectively maintained database of patients with locally advanced GBC treated between February 2009 and September 2013 with NACT. Patients received gemcitabine-platinum based regimen. RESULTS A total of 37 patients (median age: 54 years, 64.9% females) received NACT. Overall response rate was 67.5%. In total, 17 patients (46%) underwent R0 resection. Median overall survival/progression-free survival of the whole group was 13.4/8.1 months, respectively. Patients who underwent surgery had a significantly better overall survival (median not reached vs 9.5 months) and progression-free survival (25.8 vs 5.6 months), respectively. CONCLUSION NACT increases resectability and survival in patients with locally advanced GBC.


Nuclear Medicine Communications | 2013

90Y microsphere therapy: does 90Y PET/CT imaging obviate the need for 90Y Bremsstrahlung SPECT/CT imaging?

Zade Aa; Rangarajan; Nilendu Purandare; Sneha Shah; Archi Agrawal; Suyash Kulkarni; Shetty N

BackgroundTransarterial radioembolization using 90Y microspheres is a novel therapeutic option for inoperable hepatic malignancies. As these spheres are radiolucent, real-time assessment of their distribution during the infusion process under fluoroscopic guidance is not possible. Bremsstrahlung radiations arising from 90Y have conventionally been used for imaging its biodistribution. Recent studies have proved that sources of 90Y also emit positrons, which can further be used for PET/computed tomography (CT) imaging. This study aimed to assess the feasibility of 90Y PET/CT imaging in evaluating microsphere distributions and to compare its findings with those of Bremsstrahlung imaging. Materials and methodsThirty-five sessions of 90Y microsphere transarterial radioembolization were performed on 30 patients with hepatic malignancies. 90Y PET/CT imaging was performed within 3 h of therapy. Bremsstrahlung imaging was also performed for each patient. The imaging findings were compared for concordance in the distribution of microspheres. ResultsExact one-to-one correspondence between 90Y PET/CT imaging and 90Y Bremsstrahlung imaging was observed in 97.14% of cases (i.e. in 34/35 cases). Discordance was observed only in one case in which 90Y PET/CT imaging resolved the microsphere uptake in the inferior vena cava tumor thrombus, which was, however, not visualized on Bremsstrahlung imaging. ConclusionThere is good concordance in the imaging findings of 90Y PET/CT and 90Y Bremsstrahlung imaging. 90Y PET/CT imaging scores over the conventionally used Bremsstrahlung imaging in terms of better resolution, ease of technique, and comparable image acquisition time. This makes it a preferred imaging modality for assessment of the distribution of 90Y microspheres.


World Journal of Surgical Oncology | 2011

Kaposiform hemangioendothelioma in tonsil of a child associated with cervical lymphangioma: a rare case report.

Bharat Rekhi; Shweta Sethi; Suyash Kulkarni; Nirmala A. Jambhekar

Kaposiform hemangioendothelioma (KHE) is an uncommon vascular tumor of intermediate malignant potential, usually occurs in the extremities and retroperitoneum of infants and is characterized by its association with lymphangiomatosis and Kasabach-Merritt phenomenenon (KMP) in certain cases. It has rarely been observed in the head and neck region and at times, can present without KMP. Herein, we present an extremely uncommon case of KHE occurring in tonsil of a child, associated with a neck swelling, but unassociated with KMP. A 2-year-old male child referred to us with history of sore throat, dyspnoea and right-sided neck swelling off and on, since birth, was clinicoradiologically diagnosed with recurrent tonsillitis, including right sided peritonsillar abscess, for which he underwent right-sided tonsillectomy, elsewhere. Histopathological sections from the excised tonsillar mass were reviewed and showed a tumor composed of irregular, infiltrating lobules of spindle cells arranged in kaposiform architecture with slit-like, crescentic vessels. The cells displayed focal lumen formation containing red blood cells (RBCs), along with platelet thrombi and eosinophilic hyaline bodies. In addition, there were discrete foci of several dilated lymphatic vessels containing lymph and lymphocytes. On immunohistochemistry (IHC), spindle cells were diffusely positive for CD34, focally for CD31 and smooth muscle actin (SMA), the latter marker was mostly expressed around the blood vessels. Immunostaining for HHV8 was negative and Ki-67 (proliferation marker) displayed focal positivity. Diagnosis of KHE was made. Platelet count was towards lower side of range. Postoperative imaging showed discrete, multiple fluid containing lesions in the right neck that were high on T2-weighed sequences, on magnetic resonance imaging (MRI) and ipsilateral intraoral mucosal growth. Fine needle aspiration cytology (FNAC) smears from neck swelling showed blood, fluid and lymphocytes. Possibility of a coexisting lymphangioma was considered. The patient was offered sclerotherapy and is on follow-up. This case forms the second documented case of KHE at this site, along with its unique association with neck lymphangioma. KHE has distinct histopathological features and can be sorted out from its other differentials like juvenile hemangioma and Kaposis sarcoma. IHC stains are useful in substantiating a definite diagnosis.


The Journal of Clinical Endocrinology and Metabolism | 2014

Radiofrequency Ablation, an Effective Modality of Treatment in Tumor-Induced Osteomalacia: A Case Series of Three Patients

Swati Jadhav; Rajeev Kasaliwal; Nitin Shetty; Suyash Kulkarni; Krantikumar Rathod; Bhavesh Popat; Harshal Kakade; Amol Bukan; Shruti Khare; Sweta Budyal; Varsha S. Jagtap; Anurag Lila; Tushar Bandgar; Nalini S. Shah

CONTEXT Tumor-induced osteomalacia is curable if the tumors can be totally excised. However, when the tumors are present in locations that make surgery disproportionately risky, the need for less invasive strategies like radiofrequency ablation (RFA) is realized. PATIENTS AND METHODS We describe three patients with suspected tumor-induced osteomalacia who were treated in our department between 2006 and 2013 with tumors in surgically difficult locations and were subjected to single or multiple sessions of RFA. The response was documented in terms of symptomatic improvement, phosphorus normalization, and follow-up (99m)Technitium-labelled hydrazinonicotinyl-Tyr3-octreotide ((99m)Tc HYNIC TOC) scan. RESULTS Two of the three individuals, patient A (with a 1.5 × 1.2-cm lesion in the head of the right femur) and patient B (with a 1.3 × 1.2-cm lesion on the endosteal surface of the shaft of the left femur), achieved complete remission with single sessions of RFA. Three months after the procedure, (99m)Tc HYNIC TOC scans revealed the absence of uptake at the previous sites, corroborating with the clinical improvement and phosphorus normalization. Patient C had a large 5.6 × 6.5-cm complex lesion in the lower end of the left femur with irregular margins, loculations, and bone grafts placed in previous surgery. He failed to achieve remission after multiple sessions of RFA due to the complex nature of the lesion, although the tumor burden was reduced significantly as documented on serial (99m)Tc HYNIC TOC scans. CONCLUSIONS Although surgery remains the treatment of choice, RFA could be an effective, less invasive, and safe modality of treatment in judiciously selected patients.


Nuclear Medicine Communications | 2012

Comparative analysis of hepatopulmonary shunt obtained from pretherapy 99mTc MAA scintigraphy and post-therapy 90Y Bremsstrahlung imaging in 90Y microsphere therapy.

Jha Ak; Zade Aa; Rangarajan; Nilendu Purandare; Sneha Shah; Archi Agrawal; Suyash Kulkarni; Shetty N

Introduction99 mTc macroaggregate albumin (MAA) scintigraphy is routinely used to estimate the hepatopulmonary shunt (HPS) of 90Y microspheres because of their comparable average particle sizes (20–30 µm). However, the MAA particle size can vary from 10 to 90 µm. Therefore, HPS computed from 99mTc MAA scintigraphy may not accurately represent the HPS of 90Y microspheres. In view of this, the present study was undertaken to investigate the accuracy of 99mTc MAA scintigraphy in estimating the HPS of 90Y microspheres. Materials and methodsNineteen sessions of transarterial radioembolization using 90Y therasphere were carried out in 17 patients for hepatic malignancies (both primary and secondary). For each session of therapy, a pretherapeutic 99mTc MAA scintigraphy and post-therapeutic 90Y Bremsstrahlung scintigraphy were performed. The HPSs obtained from these images were compared. ResultsThe mean HPS fractions calculated from the pretherapeutic 99mTc MAA study and the post-therapeutic 90Y Bremsstrahlung images were 4.77±2.81 and 4.52±2.5%, respectively. The coefficient of correlation (r) was 0.96. Conclusion99mTc MAA scintigraphy accurately predicts the HPS of 90Y microspheres.


The Journal of Clinical Endocrinology and Metabolism | 2016

Needle(s) in the Haystack – Synchronous Multifocal Tumor Induced Osteomalacia

Anand K. Annamalai; Krishnaswamy Sampathkumar; Shubhada Kane; Nitin Shetty; Suyash Kulkarni; Venkatesh Rangarajan; Nilendu Purandare; Prathamesh Pai; Ankit D. Mahuvakar; Radhakrishnan Shanthi; Govindarajulu Suriyakumar; Vipla Puri; Subramaniam Aram; Chandrasekhar Gopalakrishnan; Mathirajan Chelian; Kg Srinivasan; Anthony J. Gill; Mark Gurnell; Roderick J. Clifton-Bligh

This is the author accepted manuscript. The final version is available from Endocrine Society via http://dx.doi.org/10.1210/jc.2015-3854

Collaboration


Dive into the Suyash Kulkarni's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mahesh Goel

Tata Memorial Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sneha Shah

Tata Memorial Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge